Interventional Cardiology
Contact Information
Location
Boswell BuildingRoom A260, Second Floor300 Pasteur Drive
Stanford, CA
Driving directions
Phone(650) 725-2621Fax
(650) 725-6766
Clinic Hours
Monday - Friday
8:00 - 5:00pm
Interventional Cardiology refers to diagnostics and non-surgical treatments of the heart. Cardiac interventions are used to diagnosis and treat coronary artery disease, valvular heart disease and congenital heart disease.
Stanford Interventional Cardiology is a world leader in percutaneous coronary revascularization, which re-establishes blood flow to the heart when its vessels have been damaged or blocked.
We perform approximately 1,000 interventions per year and offer the latest breakthroughs in the treatment of coronary artery disease and valvular heart disease.
In addition, the Stanford Heart Center offers state-of-the-art cardiac catheterization using low-radiation, high-resolution digital equipment that maximizes both patient safety and image quality.
Stanford's three cath labs perform more than 4,000 procedures annually, roughly half on an outpatient basis. Our fourth and fifth laboratories are dedicated to cardiac electrophysiology.
Balloon Aortic Valvuloplasty (BAV) in conjunction with optimal medical management remains a safe and feasible treatment option in some patients. Stanford’s Interventional Cardiologists perform BAV in severe aortic stenosis patients who require urgent non-cardiac surgery and as a bridge to transcatheter or surgical aortic valve replacement in decompensated patients who cannot tolerate more definitive therapy.
Transcatheter Aortic Valve Implantation (TAVI*) is an investigational (non FDA approved), less invasive, innovative catheter based therapy to relieve aortic stenosis; it combines the skills of Stanford’s Cardiologists, Cardiovascular Surgeons, and Cardiovascular Anesthesiologists. Outside the U.S., TAVI is assuming a major role in the management of symptomatic patients with severe aortic stenosis who are unfit to undergo open surgical AVR or who are very high risk for AVR. Stanford has been enrolling in TAVI clinical trials since 2008.